News Digest / Ticker: NTLA

Ticker: NTLA

08:01am, Thursday, May 29, 2025

Intellia Therapeutics Faces 19% Plunge Amid Safety Concerns, Analysts Urge Caution and Potential Opportunity

Intellia Therapeutics (NTLA) shares fell 19% following a safety disclosure from its Phase 3 MAGNITUDE trial. While a liver issue in one patient raised concerns, analysts maintain varied outlooks. Investors should monitor the situation closely for potential recovery.

08:50am, Tuesday, Jun 04, 2024

Cathie Wood Bets Big: Are CRISPR and Intellia Therapeutics Worth the Risk for Your Portfolio?

12:28pm, Saturday, May 25, 2024

Cathie Wood's Gambit: Are Her New High-Risk Bets the Key to Your Portfolio's Future?